Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 9/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | BAZ1A | Q9NRL2 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092786 | 1.00 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL6091760 | 0.90 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2APOLBKDM4E | |
| SCHEMBL4368860 | 0.86 | ROCK2 (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL6093269 | 0.86 | ROCK2 (0.51) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL6091814 | 0.85 | MEN1 (0.55) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL4377644 | 0.83 | METAP1 (0.54) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL4368921 | 0.83 | METAP1 (0.54) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL4372770 | 0.81 | KDR (0.55) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL4365497 | 0.81 | MAPT (0.45) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB | |
| SCHEMBL6092660 | 0.80 | SMN1; SMN2 (0.43) | ALDH1A1SMN1; SMN2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | AR, SHBG, BRCA1 | ALDH1A1 916/4885SMN1; SMN2 2413/4885MEN1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.